Altered insulin-like growth factor-2 signaling is associated with psychopathology and cognitive deficits in patients with schizophrenia

Yuan-Jian Yang, Tao Luo, Ying Zhao, Shu-Zhen Jiang, Jian-Wen Xiong, Jin-Qiong Zhan, Bin Yu, Kun Yan, Bo Wei

1 Biological Psychiatry Laboratory, Jiangxi Mental Hospital/Affiliated Mental Hospital of Nanchang University, Nanchang, P.R. China, 2 Department of Psychiatry, Jiangxi Mental Hospital/Affiliated Mental Hospital of Nanchang University, Nanchang, P.R. China, 3 Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, P.R. China

☯ These authors contributed equally to this work.
* jxmh_wb@163.com

Abstract

Background
Schizophrenia is linked with abnormal brain neurodevelopment, on which IGF-2 (insulin-like growth factor-2) has a great impact. The purpose of this study was to assess the levels of serum IGF-2 and its binding proteins IGFBP-3 and IGFBP-7 in schizophrenia patients and the associations of these proteins with schizophrenia psychopathology and cognitive deficits.

Methods
Thirty-two schizophrenia patients and 30 healthy controls were recruited. The PANSS and a neuropsychological test battery were used to assess schizophrenic symptomatology and cognition, respectively. Serum IGF-2, IGFBP-3 and IGFBP-7 levels were determined using ELISA.

Results
The schizophrenia patients had a much lower content of serum IGF-2, IGFBP-3 and IGFBP-7 than controls. For the patients, IGF-2 levels were negatively correlated with the PANSS negative scores and positively associated with working memory, attention, and executive function. The correlations between IGF-2 and the PANSS negative scores, working memory or executive function were still significant after controlling for age, sex, education level, BMI, illness history and age of onset. No significant associations of IGFBP-3 or IGFBP-7 with the PANSS scores and cognitive function were observed in the patients.
Conclusions

Our study demonstrates that serum IGF-2 was significantly correlated with negative and cognitive symptoms in patients with schizophrenia, suggesting that altered IGF-2 signaling may be implicated in the psychopathology and cognitive deficits in schizophrenia.

Background

According to a hypothesis about schizophrenia, if an adult suffers from severe mental illness, the central nervous system must have developed in a disrupted manner [1,2]. This has been widely indicated by studies in areas of epidemiology, genetics and neuroimaging [3]. For example, structural brain abnormalities are apparent in the beginning stages of schizophrenia [4,5]; there were cases in which young people frequently suffered abnormal cognition and emotion abilities just before the appearance of the mental illness [6]; and primates suffering neonatal lesions had a disabled motion capability [7].

As a type of insulin-like protein, insulin-like growth factor (IGF) is an integral component of the cell system in human bodies that serves as a communication channel regarding the physiological circumstances [8]. Accumulated evidence has convincingly demonstrated that IGF has an indispensable and crucial role to play in nerve growth [9]. During the development of brains, IGF signaling regulates the growth survival, maturation, and proliferation of many types of nerve cells, such as astrocytes, oligodendrocytes, NPC (nerve precursor cell) and NSC (nerve stem cell) [9]. In addition, IGF sends basic signals to NSC cells directing them to grow into particular lineages in early development and influences their specific biological roles in late development, with the help of other nerve signals [9]. Individuals suffering from IGF gene mutations are vulnerable to physically disabled growth, nanocephaly or intellectual disability [10,11,12].

Two different IGF ligands, insulin-like growth factor-1 (IGF-1) and insulin-like growth factor-2 (IGF-2), have drawn much attention in recent studies. Researchers have shown that IGF-1 signaling plays a role in schizophrenia pathogenesis [13,14,15]. Specifically, plasma IGF-1 levels were decreased in antipsychotic-naive schizophrenia patients and were inversely correlated with positive symptom scores and hallucination subscores [13]. Antipsychotic treatment can increase serum IGF-1 levels in schizophrenia patients, and those patients with a greater increase showed a reduction in positive symptom scores to a higher extent [14]. Palomino et al. studied and showed that the negative symptoms of schizophrenia patients were correlated with their plasma IGF-1 level, regardless of whether they were in their first psychotic episode or one year later [15]. Furthermore, IGF-1 levels were also decreased in an animal model of schizophrenia [16]. In contrast to IGF-1, IGF-2 has not been as well characterized and is expressed in brains not only during the development period but also during adulthood [9].

According to recent studies in rodents, IGF-2 not only plays an important role in neurogenesis but also in cognition. The learning process increased brain IGF-2 levels, and exogenous administration of IGF-2 strengthened memory in mice [17,18]. IGF-2 levels were decreased in the hippocampus of old rats, and administration of IGF-2 rescued their aging-related memory loss [19]. In addition, overexpression of hippocampal IGF-2 could reverse memory and synaptic injuries in APP genetically modified mice via promoting the formation of dendrite spines and the transmission of excitatory synapses [20]. Moreover, a recent small genetic study showed that one genotype (ApaI) of the IGF-2 gene, which is functionally associated with...
higher IGF-2, was associated with better selective attention performance in healthy individuals [21].

Recent reports have suggested that IGF-2 signaling is linked to schizophrenia. IGF-2 was found to be the top downregulated gene in the prefrontal cortex of schizophrenia patients in a large CommonMind consortium RNA-sequencing study [22]. Prominent hypomethylation of an enhancer within the IGF-2 gene was observed in isolated neurons from the prefrontal cortex of schizophrenia patients [23]. Akanji et al. assessed the levels of IGF-2 in male Arab patients with chronic schizophrenia, who had been receiving a stable dose of oral antipsychotic medications, showing that serum IGF-2 levels were significantly increased in schizophrenia patients and the levels of IGF-2 were positively correlated with atherogenic lipoproteins [24]. In addition, IGF-2 protein was downregulated in the hippocampus of mice lacking DiGeorge chromosome syndrome region 8 (Dgcr8), a candidate gene for 22q11.2 deletion-associated schizophrenia [25]. However, thus far, whether there is a relationship between IGF-2 signaling and the psychopathology and cognitive impairments in schizophrenia remains unknown. Therefore, this study aims to explore the potential function of IGF-2 signaling in the pathophysiology of schizophrenia by examining (1) whether serum IGF-2 was altered in Han Chinese patients who suffered from schizophrenia and (2) whether changes in IGF-2 levels were associated with the psychopathological symptoms as well as cognitive deficits of the patients. Given that the functions of IGF are modulated by IGF-binding proteins (IGFBPs), e.g., IGFBP-3 and IGFBP-7, this study also assessed changes in the levels of these binding proteins because they have been implicated in both neurodevelopment and cognitive function [18,26,27].

**Methods**

**Schizophrenia patients and healthy controls**

For this study, we recruited thirty-two schizophrenia patients who met DSM-IV criteria from Jiangxi Mental Hospital from Dec. 2016 to May 2017. Two psychiatrists confirmed their schizophrenia diagnosis. The exclusion criteria included the following: additional axis I DSM-IV diagnoses, axis II DSM-IV diagnoses, autoimmune, allergic, and neoplastic diseases, current pregnancy, and other physical disorders, such as cardiac block and cerebral infarction in the past 3 months. All the recruited patients were drug naïve or had stopped taking any antipsychotics for at least 3 months when entering the study. For controls, we recruited at the same time thirty healthy people in nearby living communities with their sex, age, BMI (body mass index) and education level similar to the patients. We assigned a clinical psychiatrist to check the controls’ healthy condition, such as their current mental condition, personal mental disorder history, and family mental disorder history. The examination showed that all the controls had a good individual and familial psychiatric history.

All the patients and controls were of Han nationality. No participants suffered from substance dependence or substance abuse, and no participants were taking immunosuppressants. We carried out this research according to the requirements of Declaration of Helsinki, and our study received approval from the Institutional Review Board at Jiangxi Mental Hospital. We obtained consent from the patients and the controls or their legal guardians in written form. The capacity to consent for the participants in this study was determined with the University of California, San Diego Brief Assessment of Capacity to Consent (UBACC), which is a 10-item scale that includes questions focusing on understanding and appreciation of the information concerning the research protocol [28]. The authors in this study had access to information that could identify individual participants after data collection.
Measurement of psychopathological symptoms and cognition

In our study, two psychiatrists were responsible for the measurement of the psychopathological symptoms for the patients by using the PANSS (Positive and Negative Syndrome Scale). Before the study, the two psychiatrists were simultaneously trained to use the PANSS. After that, they obtained an interobserver correlation coefficient of over 0.80 for the total scores of PANSS.

For the measurement of cognition, we used a set of neurocognition tests, the clinical dependability of which had already been verified and confirmed in population groups of Chinese people [29,30]. These tests consist of the following seven tasks:

TMT-A (Trail making test A): In this test, the participant is given a pencil and a piece of paper with numbered circles and asked to draw a line to connect the circles in the sequence of the numbers. The participant should draw the lines as quickly and accurately as possible, since the time taken for the drawing was used for grading.

BACS (Brief assessment of cognition in schizophrenia)-symbol coding task: In this test, the participant was given 133 pairs of digits and symbols and asked to copy the specific symbol as soon as its paired number was shown. This should be completely quickly because the number of symbols correctly finished within 120 seconds was used for the grading.

WMS-III spatial span (Wechsler memory scale-edition III-spatial span): In this test, the participant was faced with a board with ten cubes irregularly spaced on it. An administrator of this test first showed the participant combinations of the cubes in different ways and orders, forward and backward, and then asked the participant to recall the combinations. On each level of combinations, the participant was given two trials. The score was based on the number of recalled trials.

BVMT-R (Brief visual memory test-revised): In this test, the participant viewed six geometric figures, which were presented three times for ten seconds each time. Subsequently, the participant was asked to draw the figures on a piece of paper in the layout that they were presented in. The more figures that were correctly drawn, the better the score.

HVLT-R (Hopkins verbal learning test-revised): In this test, the participant was presented with twelve Chinese words, which were listed in three categories. The list was shown three times followed by a delay time of 25 to 30 minutes. Subsequently, the participant was asked to recall and speak out the words. Performance was graded in accordance with the number of words correctly recalled.

CPT-IP (Continuous performance test-identical pair): In this test, the participant saw digital numbers of 2, 3 and 4 digits flashing on a computer screen. The participant was asked to immediately click the mouse after the same number was repeatedly flashed on the screen. In this test, the participants were expected to identify the appropriate target 90 times, miss a target (i.e., trigger a false alarm) 90 times, and randomly respond approximately 270 times.

SCWT (Stroop color-word test): In this test, the participant was presented with three pages: first, a word page, on which color words are written in black; second, a color page, on which several rows of Xs were written in different colors; and third, a word-color page, on which the same color words on the first page were written in the colors from the second page, although they are not the same color as the color that the written word spells. In each trial, the participant was presented with 100 words and asked to read them as quickly as possible in 45 seconds. The number of correctly read words was used for grading.

For the above seven tests, we grouped them into six cognitive domains, i.e., executive function, attention, verbal learning, visual memory, working memory, and processing speed, which respectively cover the Stroop color-word test, CPT-IP, HVLT-R, BVMT-R, WMS-III spatial span, and TMT-A and BACS-symbol coding.
Measurement of IGF-2, IGFBP-3 and IGFBP-7

Antecubital venous blood was sampled in the morning from seven to nine after overnight fasting. After that, we separated the serum, aliquoted the samples and immediately stored them at -80˚C. We measured the levels of serum IGF-2 (Catalog # SEA051Hu), IGFBP-3 (Catalog # SEA054Hu), and IGFBP-7 (Catalog # SEB673Hu) using ELISA with available kits on the market (Wuhan USCN Business, Wuhan, China). The sensitivities for IGF-2, IGFBP-3 and IGFBP-7 were 0.264, 0.071 and 0.057 ng/ml, respectively, with variation coefficients of inter- and intra-assay of 10%, 12%, respectively. In briefly, the same volume of standard or sample was added to the appropriate microplate well with a biotin-conjugated antibody specific to IGF-2, IGFBP-3 or IGFBP-7. Next, Avidin conjugated to Horseradish Peroxidase (HRP) was added to each microplate well and incubated. After TMB substrate solution was added, only those wells that contain IGF-2, IGFBP-3 or IGFBP-7, biotin-conjugated antibody and enzyme-conjugated Avidin would exhibit a change in color. The enzyme-substrate reaction was terminated by the addition of sulphuric acid solution and the color change was measured spectrophotometrically at a wavelength of 450 nm. Each sample was measured in duplicate. We averaged the duplicate readings for each standard, control, and sample, subtracted the average zero standard optical density (O.D.), and then constructed a standard curve by plotting the mean O.D. and concentration for each standard and drew a best fit curve through the points on the graph. The concentration of IGF-2, IGFBP-3 or IGFBP-7 in the sample was then determined by comparing the O.D. of the sample to the standard curve. We assigned the same investigator, who was blind to the clinical situation, to assay all the samples. To prevent inter-assay variance, we analyzed all the samples in the same assay.

Statistical analysis

Chi-square tests were used for categoric variables, and Student’s t-test or analysis of variance (ANOVA) was used for the continuous variables for the comparison of the demographic and clinical variables between the patients and the controls. Since the IGF-2, IGFBP-3 and IGFBP-7 data were normally distributed in the healthy controls and patients (p > 0.05, Kolmogorov-Smirnov 1-sample test), we used one-way ANOVA to compare these protein levels between the two groups. We performed ANCOVA (analysis of covariance) if a crucial difference existed in the two groups to verify the influence of sex, age, education level, and BMI. For the assessment of the relationships among those factors, we used Pearson’s product moment correlation ratios. For the assessment of the relationships among serum IGF-2, IGFBP-3, or IGFBP-7 levels and psychotic and cognitive symptoms controlling for clinical variables, such as sex, age, education level, BMI, illness history, and onset age, we used partial correlation analysis in this study. We present the data from the analysis as the mean ± SD, and we adopted two-tailed significance values of 0.05.

For the calculation of cognitive scores, we first converted all the test scores into standardized z scores. For this purpose, we set the sample mean value in every measurement to zero and at the same time set the standard deviation to one. In the cognition areas with two tests, we determined summary scores by first calculating the average value of the z scores in the two tests and then converting the average value to a z score with an average value of zero and a standard deviation value of one.

Results

Demographic data and cognition

The demographic data of both the healthy controls and the schizophrenia patients are reported in Table 1. The two groups were not significantly different in terms of sex, age, education level.
We present the results of the cognition tests in Table 2 for the patients with schizophrenia and the healthy controls. The findings indicated that the schizophrenia patients performed worse than the healthy controls (all $p < 0.05$) on all the cognition tests. With the exception of the BVMT-R score ($p = 0.063$), the two groups were still very different even after we adjusted for sex, age, education level, and BMI.

### The levels of serum IGF-2, IGFBP-3 and IGFBP-7 in schizophrenia patients and healthy controls

The levels of these factors in both the healthy controls and the schizophrenia patients are shown in Table 3 and Fig 1. The patients had much lower levels of IGF-2, IGFBP-3, and IGFBP-7 than the controls (all $p < 0.05$). This was still observed even after we added sex, age, education level, and BMI to the ANOVA as covariates and examined the effects of these factors: IGF-2 ($F = 2.698$, $p = 0.040$), IGFBP-3 ($F = 2.547$, $p = 0.049$), and IGFBP-7 ($F = 2.664$, $p = 0.041$). The serum levels of these proteins in males and females in both groups were similar ($p > 0.05$). Furthermore, no correlations existed among the demographic parameters and the IGF-2, IGFBP-3 or IGFBP-7 levels for both the patients and the controls (all $p > 0.05$).

### Table 1. Demographics of patients and healthy control subjects.

|                         | Patients with schizophrenia (n = 32) | Control subjects (n = 30) | $F$     | $p$  | Adjusted $F$ | $p$  |
|-------------------------|-------------------------------------|---------------------------|---------|------|--------------|------|
| Age (years)             | 30.0 ± 8.5                          | 33.5 ± 9.1                | 2.458   | 0.122|              |      |
| Sex, M/F                | 17/16                               | 14/16                     | 0.148   | 0.701|              |      |
| Education (years)       | 11.6 ± 5.0                          | 12.6 ± 4.5                | 0.571   | 0.453|              |      |
| BMI (kg/m$^2$)          | 21.7 ± 2.3                          | 21.2 ± 1.7                | 0.954   | 0.333|              |      |
| Age of onset (years)    | 23.3 ± 5.9                          | –                         | –       | –    |              |      |
| Duration of illness (years) | 5.9 ± 5.4                         | –                         | –       | –    |              |      |
| PANSS total score       | 80.8 ± 11.1                         | –                         | –       | –    |              |      |
| Positive subscale       | 22.6 ± 4.1                          | –                         | –       | –    |              |      |
| Negative subscale       | 13.8 ± 4.5                          | –                         | –       | –    |              |      |
| General psychopathology subscale | 44.5 ± 6.0            | –                         | –       | –    |              |      |

BMI = body mass index; PANSS = Positive and Negative Syndrome Scale.

### Table 2. Comparison of cognitive function between the two groups.

| Cognitive tests       | Healthy controls (n = 30) | Patients with schizophrenia (n = 32) | $F$   | $p$  | Adjusted $F$ | $p$  |
|-----------------------|---------------------------|-------------------------------------|-------|------|--------------|------|
| TMT-A                 | 42.3 ± 9.8                | 72.3 ± 28.9                         | 31.375| <0.001| 6.627        | <0.001|
| BACS-SC               | 66.0 ± 6.3                | 35.3 ± 14.3                         | 115.986| <0.001| 24.709       | <0.001|
| WMS-III-SS            | 17.0 ± 2.2                | 14.6 ± 3.2                          | 11.985 | 0.010| 3.979        | 0.004|
| HVLT-R                | 27.3 ± 4.6                | 19.6 ± 6.0                          | 31.407 | <0.001| 6.845        | <0.001|
| BVMT-R                | 29.0 ± 10.2               | 21.3 ± 4.5                          | 4.427  | 0.040| 2.233        | 0.063|
| CPT-IP                | 3.25 ± 1.1                | 1.4 ± 0.8                           | 54.803 | <0.001| 11.128       | <0.001|
| Stroop color-word test|                          |                                    |       |      |              |      |
| Word raw score        | 82.3 ± 9.4                | 54.8 ± 15.3                         | 88.271| <0.001| 17.849       | <0.001|
| Color raw score       | 51.8 ± 9.0                | 36.6 ± 14.7                         | 23.902| <0.001| 4.837        | 0.001|
| Color-word raw score  | 37.8 ± 7.1                | 21.4 ± 12.7                         | 38.286| <0.001| 7.883        | <0.001|

TMT-A = trail making test, part A; BACS-SC = brief assessment of cognition in schizophrenia-symbol coding; WMS-III-SS = Wechsler memory scale-3rd ed.-spatial span; HVLT-R = Hopkins verbal learning test-revised; BVMT-R = brief visual-spatial memory test-revised; CPT-IP = continuous performance test-identical pairs. Adjusted $F$ indicates the $F$ value controlled for age, sex, years of education, and BMI.

https://doi.org/10.1371/journal.pone.0226688.t002
Association of serum IGF-2, IGFBP-3, and IGFBP-7 levels with psychopathological symptoms in the schizophrenia patients

For the schizophrenia patients, the correlation analysis with serum IGF-2 levels revealed a significant association between IGF-2 levels and the PANSS negative scores ($r = -0.452$, $p = 0.009$), but no significant associations between serum IGF-2 levels and PANSS total scores, positive scores or general scores (all $p > 0.05$) (Table 4). Partial correlation analysis indicated that serum IGF-2 had a significant correlation with PANSS negative scores even after controlling for sex, age, education level, BMI, illness history and onset age ($r = -0.408$, $p = 0.035$) (Table 4). However, the correlation analysis with IGFBP-3 or IGFBP-7 showed that there was no significant association of either IGFBP-3 or IGFBP-7 levels with the PANSS total or subscale scores in schizophrenia patients (all $p > 0.05$).

Correlation between IGF-2, IGFBP-3, IGFBP-7 levels and schizophrenia cognition symptoms

We grouped the cognitive tests into six cognitive areas, i.e., executive function, attention, verbal learning, visual memory, working memory, and processing speed, which respectively cover the Stroop color-word test, CPT-IP, HVLT-R, BVMT-R, WMS-III spatial span, and TMT-A and BACS symbol coding. We tested the correlations between serum IGF-2, IGFBP-3, or IGFBP-7 levels and cognitive performance for both the patients and controls. The correlation analyses revealed a crucial positive association of serum IGF-2 levels with the working memory index ($r = 0.546$, $p = 0.001$), the attention index ($r = 0.405$, $p = 0.021$), and the executive function index ($r = 0.606$, $p < 0.001$) in the schizophrenia patients (Table 4).

---

**Table 3. Serum IGF-2, IGFBP-3 and IGFBP-7 levels in the patient and control groups.**

|                | Healthy controls (n = 30) | Patients with schizophrenia (n = 32) | $F$   | $p$     | Adjusted $F$ | $p$     |
|----------------|---------------------------|--------------------------------------|-------|---------|--------------|---------|
| IGF-2 (ng/ml) | $355.7 \pm 70.4$          | $199.2 \pm 67.2$                     | 10.051| 0.002   | 2.698        | 0.040   |
| IGFBP-3 (ng/ml)| $1034.5 \pm 390.7$        | $849.7 \pm 227.1$                    | 5.633 | 0.025   | 2.547        | 0.049   |
| IGFBP-7 (ng/ml)| $33.0 \pm 12.9$           | $26.8 \pm 9.8$                       | 4.670 | 0.035   | 2.664        | 0.041   |

Adjusted $F$ indicates the $F$ value controlled for age, sex, education, and BMI.

https://doi.org/10.1371/journal.pone.0226688.t003

---

**Fig 1.** This figure presents a scattergram of serum IGF-2 (A), IGFBP-3 (B) and IGFBP-7 (C) levels from patients with schizophrenia (n = 32) and from control subjects (n = 30). The sample means are indicated by black bars. *$p < 0.05$.**

https://doi.org/10.1371/journal.pone.0226688.g001
Serum IGF-2 levels were not correlated with the processing speed index \((r = 0.158)\), the visual memory index \((r = -0.002)\) or the verbal learning index \((r = -0.198)\) (all \(p > 0.05\)). Partial correlation analysis indicated that serum IGF-2 levels still had a significant correlation with working memory \((r = 0.515, p = 0.006)\) and executive function \((r = 0.543, p = 0.003)\), even after controlling for sex, age, education level, BMI, illness history and onset age (Table 4). However, there was no significant association of either serum IGFBP-3 or IGFBP-7 levels with the cognitive test scores in the patients (all \(p > 0.05\)).

**Discussion**

The main findings in this study are as follows: (1) Serum IGF-2, IGFBP-3, and IGFBP-7 levels were significantly lower in the Chinese schizophrenia patients than the controls. (2) Serum IGF-2 levels had a negative correlation with PANSS negative symptoms and a significant positive association with working memory and executive function in patients. (3) Neither serum IGFBP-3 nor IGFBP-7 levels had a significant correlation with the psychotic and cognitive symptoms in the patients.

The IGF system is mainly composed of IGF-1 and IGF-2, the binding proteins (IGFBPs) and the cell-surface receptors. Relative to IGF-1, little is known regarding IGF-2, which is expressed in brains during fetal development and is also the most highly expressed IGF in the central nervous system of adults [31]. In biological fluids, IGF-2 usually binds with IGFBPs, which lengthen its half-life and regulate its usability and biological activity [8]. Among the IGFBPs, IGFBP-3 and IGFBP-7 have been shown to be implicated in neurodevelopment and cognition [18,26,32]. Our paper indicates that there were much lower levels of serum IGF-2, IGFBP-3 and IGFBP-7 in Chinese schizophrenia patients. After controlling for sex, age, and BMI, the content of these proteins still differed between the two groups. However, in contrast to our findings, one previous study performed in male Arab subjects demonstrated that serum IGF-2 content was much higher in schizophrenia patients, and no change was found in IGFBP-3 levels [24]. A possible explanation of the discrepancies in serum IGF-2 and IGFBP-3 levels may be different ethnicities (Chinese vs. Arab). Indeed, ethnicity impacts IGF-2 and IGFBP-3 levels in the serum of normal healthy subjects [33]. Besides, the effect of antipsychotic medications could also be a contributor to these discrepancies (stable antipsychotic medication vs. medication-free). Nevertheless, although there was an inconsistency, a change in serum IGF-2 content in schizophrenia patients was found in both studies. In light of evidence...
that IGF-2 is a potent neural growth-promoting factor and that adult-onset disorders could trace back to development [2,9], the results indicate that IGF-2 signaling might be involved in schizophrenia pathophysiology. However, whether a change of IGF-2, IGFBP-3 and IGFBP-7 in patients is caused by schizophrenia itself or other confounding factors, for example, influenced by antipsychotic drugs, is still unknown. In this study, we recruited schizophrenia patients who were not taking any antipsychotic medication for at least three consecutive months before participating in this study. Thus, we postulate that the alterations in IGF-2 signaling in schizophrenia patients is more likely to be related to the illness per se, rather than a phenomenon secondary to medication treatment. However, future studies are required to test this hypothesis by measuring IGF-2 levels in drug-naive first-episode schizophrenia patients.

This study reveals that serum IGF-2 levels had an inverse correlation with the PANSS negative scores, and this correlation remained significant after controlling for sex, age, education level, BMI, illness history, and onset age, suggesting that patients with lower IGF-2 levels were more prone to serious negative symptoms. The severity of psychotic symptoms has been shown to be associated with structural alterations in the cortex and striatum [34]. IGF-2 could promote synapse development, spine maturation, and memory formation in the brain [18,35]. Pai et al. showed that the methylation level of an enhancer within the IGF-2 gene, which targets the nearby tyrosine hydroxylase (TH) gene responsible for dopamine synthesis, was reduced in the frontal cortex of schizophrenia patients [23]. Deletion of an intergenic IGF-2 enhancer in mice led to a decrease in TH protein levels and in dopamine in the striatum [23]. In addition, pathway enrichment analysis identified that IGF-2 enhancer deletion would result in alterations in cell proliferation/development, protein synthesis, immune responses, neurodevelopment, and cytoskeletal remodeling in the frontal cortex and striatum [23]. Therefore, we postulate that decreased IGF-2 in schizophrenia might cause structural alterations and dopamine dysfunction in the cortex and striatum to aggravate the negative symptoms. However, this explanation is quite speculative. Further research using animal experiments is needed to address this assumption.

Disrupted cognition is a main characteristic of schizophrenia [3]. A variety of cognitive domains, such as processing speed, attention, working memory, visual memory, verbal learning, and executive function, have been reported to be impaired in schizophrenia. Our present study shows that schizophrenia patients displayed poorer performance in processing speed, working memory, attention, visual memory, and executive function than the normal controls, identical to previous studies [30,36]. IGF-2 has been strongly linked to cognition in the last decades [37]. Specifically, the Apal polymorphism of the IGF-2 gene was associated with the general cognition and selective attention index in healthy individuals [21]. A link was found between DNA methylation levels of IGFBP-1 gene and adult working memory performance in a monozygotic twin sample [38]. Both serum IGF-2 and IGFBP-3 levels were shown to be correlated with normal age-related cognitive decline in the Caerphilly Prospective Study from a cohort of 746 men [39]. Furthermore, injection of recombinant IGF-2 into the hippocampus enormously improved memory retention and reduced forgetting in rats [17,18]. In this study, we found that serum IGF-2 levels were positively correlated with working memory and the executive function of schizophrenia patients. Given that IGF-2 is abundantly expressed in brain regions that are relevant to working memory and executive function, like hippocampus and prefrontal cortex [18,40,41], these findings demonstrate that abnormal IGF-2 signaling is implicated in cognitive impairments of schizophrenia. IGF-2 could affect cognition via many pathways [18,25,42]. For example, administering IGF-2 in rats enhances memory retention and prevents forgetting via promoting new protein synthesis, the activation of glycogen-synthase kinase 3 and the expression of AMPA receptor in hippocampus [18]. IGF-2 treatment improved cognitive/executive functions by targeting the AMPK-mTOR-S6K pathway in a
mouse model of Autism [42]. Exogenous IGF-2 could reverse the spatial working memory deficits in Dgcr8(+/−) mice, a neurodevelopmental defect model for schizophrenia, by rescuing the proliferation of adult neural stem cells in the hippocampus [25]. However, further studies are still needed to elucidate the mechanisms of IGF-2 in the regulation of cognition in schizophrenia.

The availability and bioactivity of IGF-2 are modulated by IGFBPs in biological fluids [8]. Numerous studies have demonstrated that IGFBP-3 and IGFBP-7 are implicated in neurodevelopment and cognitive function [18,26,32]. Circulating IGFBP-3 levels were markedly decreased in AD patients and normal aging individuals, and the levels of IGFBP-3 were associated with cognitive status in these populations [43,44]. IGFBP-7 plays an important controlling role in memory consolidation [32]. Changes in IGFBP-7 levels have been correlated with postoperative cognitive dysfunction and AD-like memory impairments [27,45]. Our present study demonstrated that the levels of both serum IGFBP-3 and IGFBP-7 were markedly reduced in schizophrenia patients, while there was no significant association between either IGFBP-3 or IGFBP-7 levels and the psychotic and cognitive symptoms in the patients. These results indicated that a low level of serum IGFBP-3 and IGFBP-7 is probably a phenomenon secondary to decreased IGF-2 protein, rather than related to illness per se. However, this failure to observe a relationship might also have come from a lack of statistical power since there were not many patients and controls in this study. Further study in larger patient samples is needed to address these possibilities.

This study has the following limitations. First, although we found close associations between serum IGF-2 and the psychotic and cognitive symptoms in schizophrenia patients, the mechanism through which IGF-2 affects schizophrenia-related behaviors is still unknown. Further research using animal experiments is needed to reveal the mechanisms of IGF-2 signaling in schizophrenia. Second, only serum IGF-2 content was considered in this paper, but its content in cerebral spinal fluid was not assessed. Whether peripheral IGF-2 reflects similar changes in the central nervous system is not known. Third, the IGF system is affected by nutritional status [46]. Prealbumin and albumin, indicators of nutrition conditions, should also be assessed in the analysis of patients and controls. In addition, there were not many patients and controls in this study, and further study in larger patient samples is needed.

**Conclusions**

This study indicated that serum IGF-2, IGFBP-3 and IGFBP-7 levels of Han Chinese schizophrenia patients were decreased and serum IGF-2 levels were associated with both negative and cognitive symptoms of the patients, indicating that altered IGF-2 signaling probably contributes to the psychopathology and cognitive impairments of schizophrenia. Nevertheless, to understand the mechanism of altered IGF-2 signaling in schizophrenia patients, more studies are necessary, which could not only help to essentially understand schizophrenia but also provide new methods for the treatment of schizophrenia.

**Supporting information**

**S1 Data.**  
(ZIP)

**Author Contributions**

**Investigation:** Yuan-Jian Yang, Tao Luo, Ying Zhao, Shu-Zhen Jiang, Jian-Wen Xiong, Jin-Qiong Zhan, Bin Yu, Kun Yan.
Project administration: Bo Wei.
Writing – original draft: Yuan-Jian Yang.
Writing – review & editing: Bo Wei.

References

1. Harrison PJ (1999) The neuropathology of schizophrenia. A critical review of the data and their interpretation. Brain 122 (Pt 4): 593–624.
2. Owen MJ, O’Donovan MC, Thapar A, Craddock N (2011) Neurodevelopmental hypothesis of schizophrenia. Br J Psychiatry 198:173–175. https://doi.org/10.1192/bjp.bp.108.084384 PMID: 21357874
3. van Os J, Kapur S (2009) Schizophrenia. Lancet 374: 635–645. https://doi.org/10.1016/S0140-6736(09)60995-8 PMID: 19700006
4. Zhao C, Zhu J, Liu X, Pu C, Lai Y, et al. (2018) Structural and functional brain abnormalities in schizophrenia: A cross-sectional study at different stages of the disease. Prog Neuropsychopharmacol Biol Psychiatry 83: 27–32. https://doi.org/10.1016/j.pnpbp.2017.12.017 PMID: 29292241
5. Palaniyappan L (2017) Progressive cortical reorganisation: A framework for investigating structural changes in schizophrenia. Neurosci Biobehav Rev 79: 1–13. https://doi.org/10.1016/j.neubiorev.2017.04.028 PMID: 28501553
6. Cannon M, Caspi A, Moffitt TE, Harrington H, Taylor A, et al. (2002) Evidence for early-childhood, pan-developmental impairment specific to schizotypal disorder: results from a longitudinal birth cohort. Arch Gen Psychiatry 59: 449–456. https://doi.org/10.1001/archpsyc.59.5.449 PMID: 11982449
7. Lee H, Dvorak D, Kao HY, Duffy AM, Scharffman HE, et al. (2012) Early cognitive experience prevents adult deficits in a neurodevelopmental schizophrenia model. Neuron 75: 714–724. https://doi.org/10.1016/j.neuron.2012.06.016 PMID: 22920261
8. Fernandez AM, Torres-Alemán I (2012) The many faces of insulin-like peptide signalling in the brain. Nat Rev Neurosci 13: 225–239. https://doi.org/10.1038/nrn3209 PMID: 22430016
9. O’Kusky J, Ye P (2012) Neurodevelopmental effects of insulin-like growth factor signaling. Front Neuroendocrinol 33: 230–251. https://doi.org/10.1016/j.ynefa.2012.06.002 PMID: 22710100
10. Camacho-Hubner C, Woods KA, Miraki-Moud F, Hindmarsh PC, Clark AJ, et al. (1999) Effects of recombinant human insulin-like growth factor I (IGF-I) therapy on the growth hormone-IGF system of a patient with a partial IGF-I gene deletion. J Clin Endocrinol Metab 84: 1611–1616. https://doi.org/10.1210/jcem.84.5.5649 PMID: 10323388
11. Lehtinen MK, Zappaterra MW, Chen X, Yang YJ, Hill AD, et al. (2011) The cerebrospinal fluid provides a proliferative niche for neural progenitor cells. Neuron 69: 893–905. https://doi.org/10.1016/j.neuron.2011.01.023 PMID: 21382550
12. Baker J, Liu JP, Robertson EJ, Efstratiadis A (1993) Role of insulin-like growth factors in embryonic and postnatal growth. Cell 75: 73–82. PMID: 8402902
13. Venkatasubramanian G, Chittiprol S, Neelakantachar N, Naveen MN, Thirthall J, et al. (2007) Insulin and insulin-like growth factor-1 abnormalities in antipsychotic-naive schizophrenia. Am J Psychiatry 164: 1557–1560. https://doi.org/10.1176/appi.ajp.2007.07020233 PMID: 17889347
14. Venkatasubramanian G, Chittiprol S, Neelakantachar N, Shetty T, Gangadhar BN (2010) Effect of antipsychotic treatment on Insulin-like Growth Factor-I and cortisol in schizophrenia: a longitudinal study. Schizophr Res 119: 131–137. https://doi.org/10.1016/j.schres.2010.01.033 PMID: 20226630
15. Palomino A, Gonzalez-Pinto A, Martinez-Cengotitabengoa M, Ruiz de Azua S, Alberich S, et al. (2013) Relationship between negative symptoms and plasma levels of insulin-like growth factor 1 in first-episode schizophrenia and bipolar disorder patients. Prog Neuropsychopharmacol Biol Psychiatry 44: 29–33. https://doi.org/10.1016/j.pnpbp.2013.01.008 PMID: 23337034
16. Wesseling H, Guest PC, Lee CM, Wong EH, Rahmoune H, et al. (2014) Integrative proteomic analysis of the NMDA NR1 knockdown mouse model reveals effects on central and peripheral pathways associated with schizophrenia and autism spectrum disorders. Mol Autism 5: 38. https://doi.org/10.1186/2040-2392-5-38 PMID: 25061506
17. Stern SA, Kohtz AS, Pollonini G, Alberini CM (2014) Enhancement of memories by systemic administration of insulin-like growth factor II. Neuropsychopharmacology 39: 2179–2190. https://doi.org/10.1038/npp.2014.69 PMID: 24642597
18. Chen DY, Stern SA, Garcia-Osta A, Saunier-Reboli B, Pollonini G, et al. (2011) A critical role for IGF-II in memory consolidation and enhancement. Nature 469: 491–497. https://doi.org/10.1038/nature09667 PMID: 21270887
19. Steinmetz AB, Johnson SA, Iannitelli DE, Pollonini G, Alberini CM (2016) Insulin-like growth factor 2 rescues aging-related memory loss in rats. Neurobiol Aging 44: 9–21. https://doi.org/10.1016/j.neurobiolaging.2016.04.006 PMID: 27318130

20. Pascual-Lucas M, Viana da Silva S, Di Scala M, Garcia-Barroso C, Gonzalez-Aseguinolaza G, et al. (2014) Insulin-like growth factor 2 reverses memory and synaptic deficits in APP transgenic mice. EMBO Mol Med 6: 1246–1262. https://doi.org/10.15252/emmm.201404228 PMID: 25100745

21. Alfimova MV, Lezheiko TV, Gritsenko IK, Golimbet VE (2012) [Association of the insulin-like growth factor II (IGF2) gene with human cognitive functions]. Genetika 48: 993–998. PMID: 23035551

22. Fromer M, Roussos P, Sieberts SK, Johnson JS, Kavanagh DH, et al. (2016) Gene expression elucidates functional impact of polygenic risk for schizophrenia. Nat Neurosci 19: 1442–1453. https://doi.org/10.1038/nn.4399 PMID: 27668389

23. Pai S, Li P, Killinger B, Marshall L, Jia P, et al. (2019) Differential methylation of enhancer at IGF2 is associated with abnormally low dopamine synthesis in major psychosis. Nat Commun 10: 2046. https://doi.org/10.1038/s41467-019-09786-7 PMID: 31053723

24. Akanji AO, Ohaeri JU, Al-Shammri SA, Fatania HR (2007) Association of blood levels of insulin-like growth factor I, IGF-II and IGF binding protein (IGFBP)-3 in schizophrenic Arab subjects. Clin Chem Lab Med 45: 1229–1231. https://doi.org/10.1055/s-2007-97876-7 PMID: 17635080

25. Ouchi Y, Banno Y, Shimizu Y, Ando S, Hasegawa H, et al. (2013) Reduced adult hippocampal neurogenesis and working memory deficits in the Dgcr8-deficient mouse model of 22q11.2 deletion-associated schizophrenia can be rescued by IGF2. J Neurosci 33: 9408–9419. https://doi.org/10.1523/JNEUROSCI.2700-12.2013 PMID: 23719809

26. Ferry RJ Jr., Katz LE, Grimberg A, Cohen P, Weinzimer SA (1999) Cellular actions of insulin-like growth factor binding proteins. Horm Metab Res 31: 192–202. https://doi.org/10.1055/s-2007-978719 PMID: 10226802

27. Agbemeyeh HY, Agis-Balbo RC, Burkhardt S, Deilalle I, Fischer A (2014) Insulin growth factor binding protein 7 is a novel target to treat dementia. Neurobiol Dis 62: 135–143. https://doi.org/10.1016/j.nbd.2013.09.011 PMID: 24075854

28. Jeste DV, Palmer BW, Appelbaum PS, Golshan S, Glorioso D, et al. (2007) A new brief instrument for assessing decisional capacity for clinical research. Arch Gen Psychiatry 64: 966–974. https://doi.org/10.1001/archpsyc.64.8.966 PMID: 17679641

29. Guo X, Li J, Wang J, Fan X, Hu M, et al. (2014) Hippocampal and orbital inferior frontal gray matter volumes and cognitive deficit in treatment-naive, first-episode patients with schizophrenia. Schizophr Res 152: 339–343. https://doi.org/10.1016/j.schres.2013.12.015 PMID: 24439000

30. Yang YJ, Xiong JW, Zhao Y, Zhan JQ, Chen HB, et al. (2016) Increased plasma asymmetric dimethylarginine is associated with cognitive deficits in patients with schizophrenia. Psychiatry Res 246: 480–484. https://doi.org/10.1016/j.psychres.2016.10.015 PMID: 27794276

31. Russo VC, Gluckman PD, Feldman EL, Werther GA (2005) The insulin-like growth factor system and its pleiotropic functions in brain. Endocr Rev 26: 916–943. https://doi.org/10.1210/er.2004-0024 PMID: 16131630

32. Agis-Balboa RC, Arcos-Diaz D, Wittnam J, Govindarajan N, Blom K, et al. (2011) A hippocampal insulin-growth factor 2 pathway regulates the extinction of fear memories. EMBO J 30: 4071–4083. https://doi.org/10.1038/emboj.2011.293 PMID: 21873981

33. Hopkins KD, Lehmann ED, Jones RL, Holly JM, Cwyfan-Hughes SC, et al. (1996) Ethnicity affects IGFBP-3 and IGF-II in normal healthy young adult subjects. Clin Endocrinol (Oxf) 45: 327–331.

34. Howes OD, Cambie J, Kim E, Stahl D, Slifstein M, et al. (2012) The nature of dopamine dysfunction in schizophrenia and what this means for treatment. Arch Gen Psychiatry 69: 776–786. https://doi.org/10.1001/archgenpsychiatry.2012.169 PMID: 22474070

35. Schmeisser MJ, Baumann B, Johannsen S, Vindedal GF, Jensen V, et al. (2012) IkapaaB kinase/nuclear factor kappaB-dependent insulin-like growth factor 2 (Igf2) expression regulates synapse formation and spine maturation via Igf2 receptor signaling. J Neurosci 32: 5868–5703. https://doi.org/10.1523/JNEUROSCI.0111-12.2012 PMID: 22514330

36. Zhang XY, Liang J, Chen DC, Xiu MH, Yang FD, et al. (2012) Low BDNF is associated with cognitive impairment in chronic patients with schizophrenia. Psychopharmacology (Berl) 222: 277–284.

37. Iwamoto T, Ouchi Y (2014) Emerging evidence of insulin-like growth factor 2 as a memory enhancer: a unique animal model of cognitive dysfunction with impaired adult neurogenesis. Rev Neurosci 25: 559–574. https://doi.org/10.1515/reneuro-2014-0010 PMID: 24778346

38. Cordova-Palomera A, Alemany S, Fatjo-Vilas M, Goldberg X, Leza JC, et al. (2014) Birth weight, working memory and epigenetic signatures in IGF2 and related genes: a MZ twin study. PLoS One 9: e103639. https://doi.org/10.1371/journal.pone.0103639 PMID: 25171170
39. Green CJ, Holly JM, Bayer A, Fish M, Ebrahim S, et al. (2014) The role of IGF-I, IGF-II, and IGFBP-3 in male cognitive aging and dementia risk: the Caerphilly Prospective Study. J Alzheimers Dis 41: 867–875. https://doi.org/10.3233/JAD-132183 PMID: 24705546

40. Ye X, Kohtz A, Pollonini G, Riccio A, Alberini CM (2015) Insulin Like Growth Factor 2 Expression in the Rat Brain Both in Basal Condition and following Learning Predominantly Derives from the Maternal Allele. PLoS One 10: e0141078. https://doi.org/10.1371/journal.pone.0141078 PMID: 26495851

41. Li Y, Chen Y, Gao X, Zhang Z (2017) The behavioral deficits and cognitive impairment are correlated with decreased IGF-II and ERK in depressed mice induced by chronic unpredictable stress. Int J Neurosci 127: 1096–1103. https://doi.org/10.1080/00207454.2017.1337014 PMID: 28562144

42. Steinmetz AB, Stern SA, Kohtz AS, Descalzi G, Alberini CM (2018) Insulin-Like Growth Factor II Targets the mTOR Pathway to Reverse Autism-Like Phenotypes in Mice. J Neurosci 38: 1015–1029. https://doi.org/10.1523/JNEUROSCI.2010-17.2017 PMID: 29217883

43. Duron E, Funalot B, Brunel N, Coste J, Quinquis L, et al. (2012) Insulin-like growth factor-I and insulin-like growth factor binding protein-3 in Alzheimer’s disease. J Clin Endocrinol Metab 97: 4673–4681. https://doi.org/10.1210/jc.2012-2063 PMID: 23015654

44. Wennberg AMV, Hagen CE, Machulda MM, Hollman JH, Roberts RO, et al. (2018) The association between peripheral total IGF-1, IGFBP-3, and IGF-1/IGFBP-3 and functional and cognitive outcomes in the Mayo Clinic Study of Aging. Neurobiol Aging 66: 68–74. https://doi.org/10.1016/j.neurobiolaging.2017.11.017 PMID: 29547749

45. Jiang J, Chen Z, Liang B, Yan J, Zhang Y, et al. (2015) The change of circulating insulin like growth factor binding protein 7 levels may correlate with postoperative cognitive dysfunction. Neurosci Lett 588: 125–130. https://doi.org/10.1016/j.neulet.2014.12.046 PMID: 25543030

46. Thissen JP, Underwood LE, Ketelslegers JM (1999) Regulation of insulin-like growth factor-I in starvation and injury. Nutr Rev 57: 167–176. https://doi.org/10.1111/j.1753-4887.1999.tb06939.x PMID: 10439629